Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Return on Sales (2022 - 2025)

Historic Return on Sales for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to 0.61%.

  • Phathom Pharmaceuticals' Return on Sales rose 46300.0% to 0.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.86%, marking a year-over-year increase of 110500.0%. This contributed to the annual value of 6.05% for FY2024, which is 2892600.0% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Return on Sales stood at 0.61% for Q3 2025, which was up 46300.0% from 1.92% recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Return on Sales ranged from a high of 18.41% in Q3 2023 and a low of 116.65% during Q4 2023
  • Over the past 4 years, Phathom Pharmaceuticals' median Return on Sales value was 0.61% (recorded in 2025), while the average stood at 7.66%.
  • Its Return on Sales has fluctuated over the past 5 years, first tumbled by -1223700bps in 2023, then soared by 1141400bps in 2024.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Return on Sales stood at 5.72% in 2022, then crashed by -2138bps to 116.65% in 2023, then soared by 98bps to 2.51% in 2024, then skyrocketed by 76bps to 0.61% in 2025.
  • Its Return on Sales stands at 0.61% for Q3 2025, versus 1.92% for Q2 2025 and 3.31% for Q1 2025.